BiotechTube
HUB Organoids

HUB Organoids

Utrecht, Netherlands· Est.
huborganoids.nl
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $19.5M

Overview

HUB Organoids leverages its patented, IP-protected technology to generate physiologically relevant organoids from adult stem cells (Lgr5+) for preclinical and clinical drug testing. The company operates primarily as a service provider and technology licensor, offering drug screening, custom assay development, and its flagship 'Clinical Trial in a Dish' co-clinical testing platform. Its recent acquisition by the Life Science business of Merck KGaA, Darmstadt, Germany, provides significant resources and validation, positioning it to expand its impact across oncology, immuno-oncology, inflammatory diseases, and other therapeutic areas.

OncologyImmuno-oncologyInflammatory diseasesGenetic diseasesInfectious diseasesToxicology

Technology Platform

Proprietary, IP-protected platform for generating genetically and phenotypically stable patient-derived organoids from adult Lgr5+ stem cells, without reprogramming, for drug discovery and clinical response prediction.

Funding History

2
Total raised:$19.5M
Series A$16M
Seed$3.5M

Opportunities

The acquisition by a major life science company provides immense resources for global scaling and technology development.
The growing demand for human-relevant preclinical models to reduce drug attrition creates a large and expanding market for its CRO services and technology licenses.

Risk Factors

Competition from other advanced model systems (e.g., other organoid companies, iPSC models) and the need to continuously prove the superior predictive value of its platform.
Integration challenges and potential loss of agility following the acquisition by a large corporation.

Competitive Landscape

HUB competes in the advanced preclinical models space against other patient-derived organoid companies (e.g., Crown Bioscience, Cellesce), iPSC-based platform companies, and traditional CROs offering animal and cell line testing. Its key differentiators are its specific IP around Lgr5+ stem cell-derived organoids, its focus on epithelial tissues, and its validated 'Clinical Trial in a Dish' service.

More companies in Diagnostics & Precision Medicine →More companies in Netherlands →